Skip to main content
    B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.45
    -0.16 (-2.10%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BioCryst Pharmaceuticals Inc (BCRX) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    BioCryst Pharmaceuticals (BCRX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, BioCryst Pharmaceuticals reported EPS of $0.14, above the $0.10 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    +9.57%
    Streak
    6 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.08
    Range$0.02 - $0.17
    12 analysts
    Revenue Consensus
    $168.16M
    Range$155.94M - $181.48M
    12 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.18
    Range$0.17 - $0.18
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.15+16.7%
    60d ago$0.15+16.7%
    30d ago$0.15+16.7%
    7d ago$0.16+9.4%
    Current$0.18
    Revenue Consensus
    $166.91M
    Range$159.99M - $172.20M
    4 analysts

    Next Report

    BCRX has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 92.9% below the $1.12 reported for the quarter ended Dec 31, 2025.

    BCRX Earnings Call

    The latest BCRX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, BCRX beat 18, missed 13 and matched 8. Revenue for the quarter ended Sep 30, 2026 was $180.29M, up 13.1% from $159.40M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.14$0.10$0.10 - $0.13+40.00%Beat-12.5%21 up, 1 downNov 4, 2026$180.29M
    Jun 30, 2026$0.30$0.14$0.08 - $0.39+114.29%Beat+650.0%20 up, 1 downAug 5, 2026$218.25M
    Mar 31, 2026$0.14$0.11$0.10 - $0.14+27.27%Beat+139900.0%41 up, 0 downMay 6, 2026$156.41M
    Dec 31, 2025$1.12$0.07$0.04 - $0.12N/AN/AN/A31 up, 0 downFeb 26, 2026$406.56M
    Sep 30, 2025$0.16$0.07$0.02 - $0.15+128.57%BeatN/A41 up, 0 downNov 3, 2025$159.40M
    Jun 30, 2025$0.04$0.03$0.00 - $0.10+33.33%BeatN/A61 up, 1 downAug 4, 2025$163.35M
    Mar 31, 2025$0.00-$0.05-$0.08 - -$0.04+100.20%BeatN/A51 up, 2 downMay 5, 2025$145.53M
    Dec 31, 2024-$0.13-$0.06-$0.10 - -$0.01-115.23%MissN/A51 up, 2 downFeb 24, 2025$131.53M
    Sep 30, 2024-$0.07-$0.08-$0.09 - -$0.03+12.50%BeatN/A90 up, 0 downNov 4, 2024$117.08M
    Jun 30, 2024-$0.06-$0.16-$0.32 - -$0.14+62.50%BeatN/A110 up, 0 downAug 5, 2024$109.33M
    Mar 31, 2024-$0.17-$0.23-$0.28 - -$0.14+26.09%BeatN/A110 up, 0 downMay 6, 2024$92.76M
    Dec 31, 2023-$0.28-$0.24-$0.38 - -$0.14-16.67%MissN/A110 up, 0 downFeb 26, 2024$93.40M
    Sep 30, 2023-$0.19-$0.19-$0.41 - -$0.120.00%In lineN/A100 up, 0 downNov 2, 2023$86.74M
    Jun 30, 2023-$0.24-$0.21-$0.31 - -$0.14-14.29%MissN/A101 up, 0 downAug 3, 2023$82.49M
    Mar 31, 2023-$0.28-$0.29-$0.37 - -$0.16+3.45%BeatN/A111 up, 0 downMay 3, 2023$68.78M
    Dec 31, 2022-$0.38-$0.17-$0.45 - $0.16-123.53%MissN/A110 up, 3 downFeb 21, 2023$79.55M
    Sep 30, 2022-$0.23-$0.26-$0.46 - -$0.12+11.54%BeatN/A121 up, 3 downNov 1, 2022$75.83M
    Jun 30, 2022-$0.32-$0.35-$0.48 - -$0.20+8.57%BeatN/A120 up, 0 downAug 4, 2022$65.53M
    Mar 31, 2022-$0.40-$0.40-$0.52 - -$0.100.00%In lineN/A131 up, 0 downMay 5, 2022$49.92M
    Dec 31, 2021-$0.10-$0.30-$0.38 - -$0.21+66.67%BeatN/A130 up, 0 downFeb 23, 2022$47.16M
    Sep 30, 2021-$0.33-$0.29-$0.38 - -$0.19-13.79%MissN/A12N/ANov 3, 2021$40.99M
    Jun 30, 2021-$0.24-$0.25-$0.34 - -$0.16+4.00%BeatN/A11N/AAug 5, 2021$49.96M
    Mar 31, 2021-$0.36-$0.27-$0.31 - -$0.22-33.33%MissN/A11N/AMay 6, 2021$19.06M
    Dec 31, 2020-$0.34-$0.25-$0.36 - -$0.15-36.00%MissN/A10N/AFeb 25, 2021$4.02M
    Sep 30, 2020-$0.26-$0.26-$0.31 - -$0.170.00%In lineN/A10N/ANov 5, 2020$6.10M
    Jun 30, 2020-$0.24-$0.25-$0.30 - -$0.22+4.00%BeatN/A9N/AAug 6, 2020$2.87M
    Mar 31, 2020-$0.24-$0.24-$0.31 - -$0.210.00%In lineN/A9N/AMay 6, 2020$4.82M
    Dec 31, 2019-$0.02-$0.27-$0.39 - -$0.05+92.59%BeatN/A9N/AMar 5, 2020$39.73M
    Sep 30, 2019-$0.34-$0.31-$0.35 - -$0.27-9.68%MissN/A9N/ANov 6, 2019$1.77M
    Jun 30, 2019-$0.34-$0.32-$0.34 - -$0.25-6.25%MissN/A9N/AAug 6, 2019$1.45M
    Mar 31, 2019-$0.28-$0.28-$0.33 - -$0.220.00%In lineN/A9N/AMay 8, 2019$5.89M
    Dec 31, 2018-$0.25-$0.25-$0.32 - -$0.210.00%In lineN/A9N/AMar 4, 2019$2.73M
    Sep 30, 2018-$0.28-$0.26-$0.31 - -$0.14-7.69%MissN/A8N/ANov 6, 2018$1.45M
    Jun 30, 2018-$0.19-$0.24-$0.29 - -$0.21+20.83%BeatN/A8N/AAug 7, 2018$12.49M
    Mar 31, 2018-$0.26-$0.19-$0.27 - -$0.14-36.84%MissN/A8N/AMay 8, 2018$3.98M
    Dec 31, 2017-$0.20-$0.15-$0.21 - -$0.09-33.33%MissN/A9N/AFeb 27, 2018$3.89M
    Sep 30, 2017-$0.18-$0.18N/A0.00%In lineN/AN/AN/ANov 7, 2017$8.76M
    Jun 30, 2017-$0.21-$0.19N/A-10.53%MissN/AN/AN/AAug 7, 2017$3.10M
    Mar 31, 2017-$0.19-$0.19N/A0.00%In lineN/AN/AN/AMay 4, 2017$9.44M
    Dec 31, 2016-$0.06-$0.23N/A+73.91%BeatN/AN/AN/AFeb 27, 2017$8.98M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.32, a profit after a loss of $0.43 per share the year before. It was -$0.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.32N/A
    Dec 31, 2024-$0.43N/A
    Dec 31, 2023-$0.99N/A
    Dec 31, 2022-$1.33N/A
    Dec 31, 2021-$1.03N/A
    Dec 31, 2020-$1.08N/A
    Dec 31, 2019-$0.98N/A
    Dec 31, 2018-$0.98N/A
    Dec 31, 2017-$0.78N/A
    Dec 31, 2016-$0.75N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,35015
    2026Q2Jun 30, 20265,01614
    2026Q1Mar 31, 20264,69014
    2025Q4Dec 31, 20255,8359
    2025Q3Sep 30, 20255,61815
    2025Q2Jun 30, 20256,68016
    2025Q1Mar 31, 20258,70415
    2024Q4Dec 31, 20249,06615

    2026Q3 Earnings Call

    Opening remarks

    Nick Wilder Company Representative Good morning, and welcome to BioCryst's Third Quarter 2026 Corporate Update and Financial Results Conference Call. Participating with me today are President and CEO Charles K. Gayer, Chief Financial Officer Babar Ghias, and Chief R&D Officer Dr. Sandeep Menon. A press release and slide presentation about today's news are available on our investor relations website. Today's call contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and achievements. These statements are subject to known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to slide 2 of the presentation. In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our investor relations website. I would now like to turn the call over to Charles.

    Charles K. Gayer CEO Thanks, Nick. The third quarter was significant for BioCryst as we continue to deliver strong execution during a time of strategic evolution. On the HAE front, new patient prescriptions for ORLADEYO continued at the same high level that we have seen all year. We again added new prescribers at a rate above the average of the past several quarters, and the total base of treated patients grew at a healthy rate in the quarter. We were thrilled to launch ORLADEYO pellets for kids in August, and early signs of performance continue to be promising. Children of all ages across the 2-to-11 range have started on ORLADEYO pellets, and the mix of kids switching from other prophylaxis, those switching from acute-only treatment, and those who were treatment-naive has been balanced. This suggests the pediatric market may grow beyond the 500 patients that we have previously described. We are also looking forward to launching the recently approved 150-milligram ORLADEYO pellets at the upcoming American College of Allergy, Asthma, and Immunology meeting this month. This new formulation for ages 12 and up provides an option for kids who started on pellets, for adolescents and adults who have difficulty swallowing a capsule, or for anyone who simply prefers the pellet formulation. We are looking forward to generating real-world evidence to track the progress and patterns of use for all patients treated with ORLADEYO pellets. During the third quarter, we also implemented the transition to CareMed as our sole-source pharmacy partner for shipments to patients.

    Frequently Asked Questions About BCRX

    When is BioCryst Pharmaceuticals's next earnings date?

    BioCryst Pharmaceuticals's next earnings report is expected for Feb 24, 2027.

    Did BCRX beat earnings estimates last quarter?

    Yes. BioCryst Pharmaceuticals reported EPS of $0.14 for the quarter ended Sep 30, 2026, above the $0.10 estimate, a 40.00% surprise.

    What EPS do analysts expect from BCRX next quarter?

    The consensus EPS estimate for BioCryst Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.08 from 12 analysts, with estimates from $0.02 to $0.17.

    How often does BCRX beat earnings estimates?

    BioCryst Pharmaceuticals beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +42.62%.